Saudi Arabia Respiratory Devices Market: Chronic Disease Burden, Home Care & Growth Outlook

According to IMARC Group's latest research publication, Saudi Arabia respiratory devices market size reached USD 214.2 Million in 2025. The market is projected to reach USD 336.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2026-2034.

How AI is Reshaping the Future of Saudi Arabia Respiratory Devices Market

• Smart Diagnostics with Precision: AI algorithms analyze CT scans and chest X-rays with 91% sensitivity, detecting lung nodules and pneumonia far faster than traditional methods, helping Saudi clinics diagnose COPD and asthma earlier.
• Real-Time Patient Monitoring: Wearable devices powered by AI track breathing patterns, cough sounds, and oxygen levels continuously, alerting healthcare providers instantly when a patient's condition worsens, especially valuable for chronic respiratory patients.
• Personalized Treatment Plans: Machine learning systems study patient history and therapy responses to create tailored treatment protocols, optimizing inhaler usage and ventilator settings based on individual breathing patterns rather than one-size-fits-all approaches.
• Home-Based Respiratory Care: AI-enabled spirometers and smart inhalers allow Saudi patients to monitor lung function from home with clinical-grade accuracy, reducing hospital visits while transmitting reliable data directly to physicians through connected platforms.
• Ventilator Optimization in ICUs: Advanced algorithms adjust ventilator pressure and oxygen delivery in real-time based on patient respiratory mechanics, cutting over-ventilation risks and improving outcomes for critically ill patients in Saudi intensive care units.

How Vision 2030 is Revolutionizing Saudi Arabia Respiratory Devices Industry

Vision 2030 is fundamentally transforming respiratory healthcare across the Kingdom through massive infrastructure investments and digital modernization initiatives. The government allocated USD 50.4 billion (16.96% of the national budget) to healthcare in 2023, with USD 5 billion specifically earmarked for health sector modernization including respiratory device procurement. The Ministry of Health has integrated oxygen concentrators and advanced respiratory equipment into the national COPD management strategy, aiming to reduce hospital admissions through expanded home-based care programs. Vision 2030's emphasis on healthcare innovation has accelerated the rollout of digital health applications like Sehhaty and Mawid, making respiratory care more accessible across all regions. The plan targets raising life expectancy from 75 to 80 years by 2030, with respiratory disease identified as a key focus area. Additionally, the Saudi Food and Drug Authority is encouraging local manufacturing partnerships through public-private collaborations, reducing import dependency and supporting the Kingdom's goal of building a self-sufficient medical device ecosystem that serves both domestic needs and regional export markets.

Download the Sample Report to Understand Market Trends and Outlook

Saudi Arabia Respiratory Devices Market Trends & Drivers:

The respiratory devices market in Saudi Arabia is experiencing robust expansion driven by the alarming rise in chronic respiratory conditions across the population. The prevalence of COPD stands at approximately 2,053 cases per 100,000 people, with over 434,000 diagnosed cases reported as of recent data—representing a 329% increase since the early 1990s. Asthma affects an estimated 14% to 25% of children in certain regions, making it one of the most prevalent chronic illnesses in the Kingdom. The high smoking rate, estimated at around 28% among adults over 40 years old, combined with exposure to air pollution, dust storms common in cities like Riyadh, and indoor biomass fuel use, continues to fuel respiratory disease incidence. The COVID-19 pandemic highlighted critical gaps in respiratory care capacity—during peak periods, hospital admission rates for COVID-19 patients ranged from 11% to 62%, prompting the Ministry of Health to supply an additional 3,728 hospital beds with mechanical ventilators. This crisis permanently shifted healthcare priorities and accelerated investments in respiratory infrastructure. Post-COVID syndrome has further exacerbated the burden, with many patients experiencing long-term respiratory symptoms requiring ongoing device support. The aging demographic is another major catalyst, with the population aged 60 and above projected to rise from 5.5% in 2020 to 11% by 2030, significantly increasing the pool of individuals susceptible to age-related respiratory conditions.

Technological innovation is reshaping how respiratory care is delivered throughout the Kingdom. Portable oxygen concentrators, non-invasive ventilators, and smart nebulizers are transitioning respiratory treatment from hospital-centric to home-based models, offering patients greater mobility and independence. Smart inhalers equipped with sensors and Bluetooth connectivity are gaining traction, helping patients track medication adherence and sending real-time data to healthcare providers for better disease management. These connected devices integrate seamlessly with Saudi Arabia's expanding digital health infrastructure, including telemedicine platforms that enable remote monitoring of respiratory parameters. The shift toward home healthcare gained significant momentum during the pandemic and continues to grow as patients increasingly prefer self-managing their conditions in comfortable home environments. Device manufacturers are responding by developing user-friendly interfaces, longer battery life, and quieter operation to enhance patient comfort. The integration of advanced bioreceptors and digital monitoring capabilities in respiratory devices is improving clinical outcomes while reducing the need for frequent in-person consultations. Wearable respiratory belts and non-contact monitoring technologies are emerging as valuable tools for continuous health tracking, particularly for sleep apnea and chronic disease management. These innovations align perfectly with Vision 2030's digital transformation objectives and are supported by substantial government investments in health information technology, including USD 1.5 billion allocated specifically for digital health systems and the establishment of 10 teleradiology enterprises across the Kingdom.

The healthcare infrastructure landscape is undergoing a dramatic transformation that directly benefits the respiratory devices sector. Vision 2030's Healthcare Sector Transformation Program is driving the expansion of hospital capacity, with projections to add between 26,000 to 43,000 new hospital beds by 2030 to accommodate the population expected to reach 45 million. The construction of specialized medical cities and respiratory care centers is creating dedicated facilities equipped with state-of-the-art diagnostic and therapeutic devices. Public-Private Partnerships are playing an increasingly important role, with the government actively encouraging private sector participation to accelerate infrastructure development and improve service delivery. The Saudization initiative, which seeks to replace expatriate workers with qualified Saudi nationals, is simultaneously driving demand for skilled medical professionals and advanced respiratory equipment that can operate with minimal expert oversight. Medical tourism is expanding as the Kingdom positions itself as a regional healthcare hub, attracting patients from neighboring countries and driving demand for world-class respiratory care facilities. The establishment of health clusters and the privatization of certain healthcare services under Vision 2030 are fostering competition and innovation, encouraging hospitals to adopt the latest respiratory technologies to maintain competitive advantage. Regulatory oversight by the Saudi Food and Drug Authority ensures that both imported and locally assembled respiratory devices meet stringent international safety and performance standards, building trust among healthcare providers and patients. Companies like Oxus Arabia are establishing manufacturing operations within the Kingdom, contributing to localization goals while improving product availability and reducing costs. These infrastructure improvements, combined with growing awareness about respiratory health and early diagnosis campaigns, are creating a fertile environment for sustained market growth across all device categories—from diagnostic tools like spirometers and pulse oximeters to therapeutic equipment including CPAP machines, ventilators, and nebulizers.

Saudi Arabia Respiratory Devices Industry Segmentation:

The report has segmented the market into the following categories:

Type Insights:

• Diagnostic and Monitoring Devices
• Spirometers
• Sleep Test Devices
• Peak Flow Meters
• Pulse Oximeters
• Capnographs
• Others

Therapeutic Devices

• CPAP Devices
• BiPAP Devices
• Humidifiers
• Nebulizers
• Oxygen Concentrators
• Ventilators
• Inhalers
• Others

• Disposables
• Masks
• Breathing Circuits
• Others

Regional Insights:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in Saudi Arabia Respiratory Devices Market

• December 3, 2024: Bedfont® Scientific Limited partnered with Tebaba Medical Services to distribute their NObreath® FeNO device and Gastrolyzer® range of devices in the Middle East, advancing respiratory and gastrointestinal diagnostic solutions in the region. The NObreath® device helps diagnose and manage asthma by measuring nitric oxide levels in exhaled breath.
• September 24, 2024: EVA Pharma implemented cutting-edge innovation to develop dry powder inhalation products for respiratory patients in Saudi Arabia, aligned with the country's Vision 2030 to enhance healthcare and promote local investments. The company's commitment to sustainable and affordable healthcare solutions is showcased through localization of specialized R&D know-how at its complex in Sudair.
• July 26, 2024: Lallemand Pharma and Avalon Pharma partnered to enhance respiratory healthcare in Saudi Arabia by combining their expertise and resources. The introduction of the Salinose® Bagonvalve technology aims to promote respiratory well-being through precise nasal irrigation and use of clinical efficacy ingredients.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.